If I've heard it once, I've heard it (not yet) a hundred times.

摘要

Sirolimus bests paclitaxel. Everolimus bests pacli-taxel [1]. Sirolimus and everolimus are not inferior to paclitaxel in diabetic patients as initially thought, probably not as good in smaller vessels [2]. All drug-elut-ing stent costs are about the same give or take some contractual nuances and deliverability of the second generation stents are equally good, as well. So, should we continue reading and hearing about this seemingly irrelevant comparison of new and old [3]?